Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...
Shares of Lexicon Pharmaceuticals , Inc. (Nasdaq: NASDAQ: LXRX) plummeted 50% following the announcement of topline results from its Phase 2b PROGRESS study, whic ...
Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) tumbled 55% after the company announced topline results from its PROGRESS Phase 2b study, which evaluated pilavapadin in ...
Q2 2025 Earnings Call Transcript February 28, 2025 Silviu Itescu: Good morning, everybody. I’m Silviu Itescu. I’m the Chief ...
The American Society of Anesthesiologists released new guidance on the safe use of ketamine for nonanesthesia purposes, such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback